Diabetes and bone health

Maturitas

Volumn 76, Issue 3, 2013, Pages 253-259

  Antonopoulou, Marianna ^a   Bahtiyar, Gül ^a,b   Banerji, Mary Ann ^a   Sacerdote, Alan S ^a,b  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes; Fractures; Osteoporosis; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIURETIC AGENT; FUROSEMIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; LOOP DIURETIC AGENT; METFORMIN; METFORMIN PLUS ROSIGLITAZONE; ROSIGLITAZONE; SULFONYLUREA; THIAZIDE DIURETIC AGENT; TROGLITAZONE;

BONE DENSITY; BONE TURNOVER; CLINICAL EVALUATION; DIABETES MELLITUS; DRUG EFFECT; FRACTURE; GLYCEMIC CONTROL; HEALTH STATUS; HUMAN; MONITORING; MUSCULOSKELETAL FUNCTION; NONHUMAN; REVIEW; RISK ASSESSMENT; SCREENING;

ADVANCED GLYCATION ENDPRODUCTS; AGES; BMD; BONE MINERAL DENSITY; CAH; CONGENITAL ADRENAL HYPERPLASIA; DIABETES; DIABETES MELLITUS; DIPEPTYDIL PETPTIDASE-4; DM; DPP-4; DUAL-ENERGY X-RAY ABSORPTIOMETRY; DXA; FOLLICLE STIMULATING HORMONE; FRACTURE RISK ASSESSMENT TOOL; FRACTURES; FRAX; FSH; GASTRIC INHIBITORY POLYPEPTIDE; GH; GIP; GLP; GLUCAGON LIKE PEPTIDE; GROWTH HORMONE; IGF-1; IGFBP3; INSULIN LIKE GROWTH FACTOR 1; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; LH; LUTEINIZING HORMONE; OSTEOPOROSIS; PARATHYROID HORMONE; PCOS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA; POLYCYSTIC OVARIAN SYNDROME; PPAR-GAMMA AGONISTS; PTH; SEX HORMONE BINDING GLOBULIN; SHBG; THIAZOLIDINEDIONES; TZDS;

BONE AND BONES; BONE DENSITY; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES;

EID: 84887459393     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2013.04.004     Document Type: Review

References (70)

1. O. Johnell, and J.A. Kanis An estimate of the worldwide prevalence and disability associated with osteoporotic fractures Osteoporosis International 17 12 2006 1726
2. H.E. Meyer, A. Tverdal, and J.A. Falch Risk factors for hip fracture in middle-aged Norwegian women and men American Journal of Epidemiology 137 11 1993 1203 1211
3. A. Schwartz, D. Sellmeyer, and E. Kristine Older women with diabetes have an increased risk of fracture: a Prospective Study Journal of Clinical Endocrinology and Metabolism 86 2001 32 38
4. K.K. Nicodmus, and A.R. Folsom Iowa Women's Health Study, Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women Diabetes Care 24 7 2001 1192 1197
5. I.I. de Liefde, M. van der Klift, C.E. de Laet, P.L. van Daele, A. Hofman, and H.A. Pols Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study Osteoporosis International 16 12 2005 1713 1720
6. K.J. Ottenbacher, G.V. Ostir, M.K. Peek, J.S. Goodwin, and K.S. Markides Diabetes mellitus as a risk factor for hip fracture in Mexican American older adults Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 57 10 2002 M648 M653
7. E.S. Strotmeyer, J.A. Cauley, and A.V. Schwartz Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study Archives of Internal Medicine 165 14 2005 1612 1617
8. R.M. Yoho, J. Frerichs, N.B. Dodson, R. Greenhagen, and S. Geletta A comparison of vitamin D levels in nondiabetic and diabetic patient populations Journal of the American Podiatric Medical Association 99 1 2009 35 41
9. P. Vestergaard Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes - a meta-analysis Osteoporosis International 18 4 2007 427 444
10. E.Y. Liu, J. Wactawski-Wende, R.P. Donahue, J. Dmochowski, K.M. Hovey, and T. Quattrin Does low bone mineral density start in post-teenage years in women with type 1 diabetes? Diabetes Care 26 8 2003 2365 2369
11. D. Vashishth Advanced glycation end-products and bone fractures IBMS BoneKEy 6 2009 268 278
12. W.H. Herman, Y. Ma, and G. Uwafo Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the diabetes prevention program Diabetes Care 30 2007 2453 2457
13. M. Inaba, M. Terada, and H. Koyama Influence of high glucose on 1,25-dihydroxyvitamin D3-induced effect on human osteoblast-like MG-63 cells Journal of Bone and Mineral Research 10 7 1995 1050 1056
14. M. Inaba, Y. Nishizawa, and K. Mita Poor glycemic control impairs the response of biochemical parameters of bone formation and resorption to exogenous 1,25-Dihydroxyvitamin D3 in Patients with Type 2 Diabetes Osteoporosis International 9 6 1999 525 531
15. K.K. Danielson, M.E. Elliott, T. LeCaire, Binkley, and M. Palta Poor glycemic control is associated with low BMD detected in premenopausal women with Type 1 Diabetes Osteoporos International 20 6 2009 923 933
16. M.T. Rosato, S.H. Schneider, and S.A. Shapses Bone turnover and insulin-like growth factor I levels increase after improved glycemic control in noninsulin-dependent diabetes mellitus Calcified Tissue International 63 2 1998 107 111
17. R. Okazaki, Y. Totsuka, and K. Hamano Metabolic improvement of poorly controlled noninsulin-dependent diabetes mellitus decreases bone turnover Journal of Clinical Endocrinology and Metabolism 82 9 1997 2915 2920
18. J.M. Kindblom, C. Ohlsson, and O. Ljunggren Plasma osteocalcin is inversely related to fat mass and plasma glucose in elderly Swedish men Journal of Bone and Mineral Research 24 5 2009 785 791
19. I. Kanazawa, T. Yamaguchi, and M. Yamamoto Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus Journal of Clinical Endocrinology and Metabolism 94 1 2009 45 49
20. K.J. Motyl, L.R. McCabe, and A.V. Schwartz Bone and glucose metabolism: a two-way street Archives of Biochemistry and Biophysics 503 1 2010 2 10
21. M. Ferron, E. Hinoi, G. Karsenty, and P. Ducy Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice Proceedings of the National Academy of Sciences of the United States of America 105 13 2008 5266 5270
22. N.C. Thalassinos, P. Hadjiyanni, M. Tzanela, C. Alevizaki, and D. Philokiprou Calcium metabolism in diabetes mellitus: effect of improved blood glucose control Diabetic Medicine 10 4 1993 341 344
23. S.E. Kahn, B. Zinman, and J.M. Lachin Rosiglitazone-associated fractures in type 2 diabetes: an analysis from A Diabetes Outcome Progression Trial (ADOPT) Diabetes Care 31 2008 845 851
24. A.V. Schwartz, D.E. Sellmeyer, and E. Vittinghoff Thiazolidinedione use and bone loss in older diabetic adults Journal of Clinical Endocrinology and Metabolism 91 9 2006 3349 3354
25. A. Grey, M. Bolland, and G. Gamble The peroxisome proliferator-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial Journal of Clinical Endocrinology & Metabolism 92 2007 1305 1310
26. S. Yaturu, B. Bryant, and S.K. Jain Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men Diabetes Care 30 2007 1574 1576
27. A.A. Ali, R.S. Weinstein, S.A. Stewart, A.M. Parfitt, S.C. Manolagas, and R.L. Jilka Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation Endocrinology 146 3 2005 1226 1235
28. M.A. Sorocéanu, D. Miao, X.Y. Bai, H. Su, D. Goltzman, and A.C. Karaplis Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis Journal of Endocrinology 183 2004 203 216
29. R. Okazaki, M. Miura, and M. Toriumi Short-term treatment with troglitazone decreases bone turnover in patients with type 2 diabetes mellitus Endocrine Journal 46 6 1999 795 801
30. Z. Berberoglu, A. Gursoy, N. Bayraktar, A.C. Yazici, N. Bascil Tutuncu, and N. Gunever Demirag Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women Journal of Clinical Endocrinology and Metabolism 92 9 2007 3523 3530
31. S. Watanabe, Y. Takeuchi, S. Fukumoto, H. Fujita, T. Nakano, and T. Fujita Decrease in serum leptin by troglitazone is associated with preventing bone loss in type 2 diabetic patients Journal of Bone and Mineral Metabolism 21 3 2003 166 171
32. L.G. Raisz, B. Wiita, and A. Artis Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women Journal of Clinical Endocrinology and Metabolism 81 1 1996 37 43
33. C. Slemenda, C. Longcope, M. Peacock, S. Hui, and C.C. Johnston Sex steroids, bone mass, and bone loss. A prospective study of pre-, peri-, and postmenopausal women Journal of Clinical Investigation 97 1 1996 14 21
34. C. Longcope, R.S. Baker, S.L. Hui, and C.C. Johnston Androgen and estrogen dynamics in women with vertebral crush fractures Maturitas 6 4 1984 309 318
35. R. Singh, J.N. Artaza, and W.E. Taylor Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors Endocrinology 147 1 2006 141 154
36. A. Imam, J. Iqbal, and H.C. Blair Role of the pituitary-bone axis in skeletal pathophysiology Current Opinion in Endocrinology, Diabetes & Obesity 16 6 2009 423 429
37. Z.R. Xu, A.H. Wang, and X.P. Wu Relationship of age-related concentrations of serum FSH and LH with bone mineral density, prevalence of osteoporosis in native Chinese women Clinica Chimica Acta 400 2009 8 13
38. N. Danilovich, P.S. Babu, W. Xing, M. Gerdes, H. Krishnamurthy, and M.R. Sairam Estrogen deficiency, obesity, and skeletal abnormalities in follicle-stimulating hormone receptor knockout (FORKO) female mice Endocrinology 141 2000 4295 4308
39. H. Vierhapper, P. Nowotny, and W. Waldhäusl Reduced production rates of testosterone and dihydrotestosterone in healthy men treated with rosiglitazone Metabolism: Clinical and Experimental 52 2 2003 230 232
40. L. Saha, S. Kaur, and P.K. Saha Pharmacotherapy of polycystic ovary syndrome - an update Fundamental and Clinical Pharmacology 26 1 2012 54 62
41. L. Schurman, A.D. McCarthy, and C. Sedlinsky Metformin reverts deleterious effects of advanced glycation end-products (AGEs) on osteoblastic cells Experimental and Clinical Endocrinology and Diabetes 116 6 2008 333 340
42. Q.G. Mai, Z.M. Zhang, and S. Xu Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats Journal of Cellular Biochemistry 112 10 2011 2902 2909
43. C. Sedlinsky, M.S. Molinuevo, and A.M. Cortizo Metformin prevents anti-osteogenic in vivo and ex vivo effects of rosiglitazone in rats European Journal of Pharmacology 668 3 2011 477 485
44. E. Osehobo, I. Shaw, and A. Sacerdote Do insulin sensitizers repair the gene defect in non-classical adrenal hyperplasia? ACP New York Chapter, 2000 New York Downstate scientific meeting& The 2000 Endocrine Society annual meeting. 2000
45. G. Bahtiyar, and A. Sacerdote Management approaches to congenital adrenal hyperplasia in adolescents and adults; latest therapeutic developments Amar Chaterjee Amenorrhea 2011 Intech 85 90
46. G. Bahtiyar, K. Weiss, and A.S. Sacerdote Novel endocrine disrupter effects of classic and atypical antipsychotic agents and divalproex: induction of adrenal hyperandrogenism, reversible with metformin or rosiglitazone Endocrine Practice 13 6 2007 601 608
47. L.A. Casulari, A.D. Caldas, L. Domingues Casulari Motta, and A. Lofrano-Porto Effects of metformin and short-term lifestyle modification on the improvement of male hypogonadism associated with metabolic syndrome Minerva Endocrinologica 35 3 2010 145 151
48. J.L. Borges, J.P. Bilezikian, and A.R. Jones-Leone A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naïve type 2 diabetics Diabetes, Obesity and Metabolism 13 11 2011 1036 1046
49. I. Kanazawa, T. Yamaguchi, M. Yamamoto, and T. Sugimoto Relationship between treatments with insulin and oral hypoglycemic agents versus the presence of vertebral fractures in type 2 diabetes mellitus Journal of Bone and Mineral Metabolism 28 5 2010 554 560
50. M. Monami, I. Dicembrini, A. Antenore, and E. Mannucci Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials Diabetes Care 34 2011 2474 2476
51. L.L. Baggio, and D.J. Drucker Biology of incretins: GLP-1 and GIP Gastroenterology 132 2007 2131 2157
52. K.M. Thrailkill Insulin-like growth factor-I in diabetes mellitus: its physiology, metabolic effects, and potential clinical utility Diabetes Technology & Therapeutics 2 1 2000 69 80
53. J. Verhaeghe, A.M. Suiker, and W.J. Visser The effects of systemic insulin, insulin-like growth factor-I and growth hormone on bone growth and turnover in spontaneously diabetic BB rats Journal of Endocrinology 134 3 1992 485 492
54. I. Kanazawa, T. Yamaguchi, M. Yamamoto, M. Yamauchi, S. Yano, and T. Sugimoto Serum insulin-like growth factor-I level is associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes mellitus Osteoporosis International 18 12 2007 1675 1681
55. D.M. Thomas, D.K. Hards, S.D. Rogers, K.W. Ng, and J.D. Best Insulin receptor expression in bone Journal of Bone and Mineral Research 11 1996 1312 1320
56. P. Vestergaard, L. Rejnmark, and L. Mosekilde Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk Diabetologia 48 2005 1292 1299
57. L.L. Lipscombe, S.A. Jamal, G.L. Booth, and G.A. Hawker The risk of hip fractures in older individuals with diabetes Diabetes Care 30 4 2007 835 841
58. A.V. Schwartz, K.L. Margolis, and D.E. Sellmeyer Intensive glycemic control is not associated with fractures or falls in the ACCORD randomized trial Diabetes Care 35 70 2012 1525 1531
59. F.E. Heidrich, A. Stergachis, and K.M. Gross Diuretic drug use and the risk for hip fracture Annals of Internal Medicine 115 1 1991 1 6
60. J.A. Cauley, S.R. Cummings, and D.G. Seeley Effects of thiazide diuretic therapy on bone mass, fractures, and falls, The Study of Osteoporotic Fractures Research Group Annals of Internal Medicine 118 9 1993 666 673
61. K. Aung, and T. Htay Thiazide diuretics and the risk of hip fracture Cochrane Database of Systematic Reviews 10 2011 Art. No.: CD005185
62. D.J. Morton, E.L. Barrett-Connor, and S.L. Edelstein Thiazides and bone mineral density in elderly men and women American Journal of Epidemiology 139 11 1994 1107 1115
63. L.S. Lim, H.A. Fink, M.A. Kuskowski, B.C. Taylor, Jt Schousboe, and K.E. Ensrud Loop diuretic use and increased rates of hip bone loss in older men: The Osteoporotic Fractures in Men Study Archives of Internal Medicine 168 7 2008 735 740
64. M.E. Ooms, P. Lips, A. Van Lingen, and H.A. Valkenburg Determinants of bone mineral density and risk factors for osteoporosis in healthy elderly women Journal of Bone and Mineral Research 8 6 1993 669 675
65. L.M. Giangregorio, W.D. Leslie, and L.M. Lix FRAX underestimates fracture risk in patients with diabetes Journal of Bone and Mineral Research 27 2 2012 301 308
66. D. Chappard, M. Moquereau, and P. Mercier Ex vivo bone mineral density of the wrist: influence of medullar fat Bone 34 6 2004 1023 1028
67. M. Yamamoto, T. Yamaguchi, M. Yamauchi, S. Yano, and T. Sugimoto Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes Journal of Clinical Endocrinology and Metabolism 93 3 2008 1013 1019
68. I. Kanazawa, T. Yamaguchi, and T. Sugimoto Baseline serum total adiponectin level is positively associated with changes in bone mineral density after 1-year treatment of type 2 diabetes mellitus Metabolism: Clinical and Experimental 59 9 2010 1252 1256
69. D.C. Bauer, W.S. Browner, and J.A. Cauley Factors associated with appendicular bone mass in older women. The Study of Osteoporotic Fractures Research Group Annals of Internal Medicine 118 9 1993 657 665
70. S. Yamagishi Role of advanced glycation end products (AGEs) in osteoporosis in diabetes Current Drug Targets 12 2011 2096 2102